SciELO - Scientific Electronic Library Online

 
vol.26 suppl.1Efficacy and tolerance of pentamidine for treatment of cutaneous leishmaniasis caused by por L. (V) panamensis in ColombiaOral miltefosine to treat leishmaniasis author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Biomédica

Print version ISSN 0120-4157On-line version ISSN 2590-7379

Abstract

SOTO, Jaime  and  SOTO, Paula. Current situation and future of antileihmanial therapy in Colombia. Biomédica [online]. 2006, vol.26, suppl.1, pp.194-206. ISSN 0120-4157.

Pentavalent antimonials are the first choice to treat leishmaniasis in Colombia. However, a 600% increase in the total dose has been necessary in order to maintain their efficacy. Cure rates varying between 93 and 25% can reflect differences in parasite susceptibility, but are more likely secondary to deficiencies in compliance with treatment guidelines. We review the current situation of efficacy and use of pentavalent antimony compounds, amphotericin B, pentamidine and miltefosine and attempt a projection for the next following years. To determine the real situation of response to antileishmanial drugs and to extend their useful life, the establishment of surveillance mechanisms to cover all factors involved is necessary. A sentinel site surveillance strategy to allow punctual observations in time, in specific geographical areas and in particular local situations, is proposed.

Keywords : Leishmaniasis [therapy]; epidemiologic surveillance; drug resistance; treatment outcome; effectiveness.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License